Management of side-effects.
Rosa I.
Clin Res Hepatol Gastroenterol. 2011 Dec;35 Suppl 2:S69-74. doi: 10.1016/S2210-7401(11)70011-0.
Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study.
Gragnani L, Fabbrizzi A, Triboli E, Urraro T, Boldrini B, Fognani E, Piluso A, Caini P, Ranieri J, Monti M, Laffi G, Zignego AL.
Dig Liver Dis. 2014 Sep;46(9):833-7. doi: 10.1016/j.dld.2014.05.017. Epub 2014 Jun 19.
Chronic hepatitis C genotype 1 virus: who should wait for treatment?
Tovo CV, de Mattos AA, de Almeida PR.
World J Gastroenterol. 2014 Mar 21;20(11):2867-75. doi: 10.3748/wjg.v20.i11.2867.
Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients.
Helal GK, Gad MA, Abd-Ellah MF, Eid MS.
J Med Virol. 2016 Dec;88(12):2170-2178. doi: 10.1002/jmv.24575. Epub 2016 May 25.
Triple Threat: Triple Pathogen Endocarditis.
Gonzalez JM, Lowenhaar G, Ramgopal M, Chalasani P.
Cureus. 2023 Oct 28;15(10):e47860. doi: 10.7759/cureus.47860. eCollection 2023 Oct.
The effect of direct acting antiviral agents on vascular endothelial function in Egyptian patients with chronic hepatitis C virus infection.
Freekh DA, Helmy MW, Said M, El-Khodary NM.
Saudi Pharm J. 2021 Oct;29(10):1120-1128. doi: 10.1016/j.jsps.2021.08.006. Epub 2021 Aug 4.
Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions.
Teixeira R, Nascimento Yde A, Crespo D.
Braz J Infect Dis. 2013 Mar-Apr;17(2):194-204. doi: 10.1016/j.bjid.2012.10.010. Epub 2013 Mar 9.
Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis.
Saxena V, Manos MM, Yee HS, Catalli L, Wayne E, Murphy RC, Shvachko VA, Pauly MP, Chua J, Monto A, Terrault NA.
Aliment Pharmacol Ther. 2014 May;39(10):1213-24. doi: 10.1111/apt.12718. Epub 2014 Mar 24.
Drug eruptions induced by telaprevir in patients with chronic hepatitis C virus genotype 1 infection: a prospective study.
Toro Montecinos M, Carrascosa Carrillo JM, Vilavella Rius M, Bielsa Marsol I, Plana Pla A, Morillas Cunill R, Planas Vilà R, Masnou Ridaura H, López Escartin D, Ferrándiz Foraster C.
Actas Dermosifiliogr. 2015 Apr;106(3):219-25. doi: 10.1016/j.ad.2014.07.004. Epub 2014 Oct 26.
Telaprevir: changing the standard of care of chronic hepatitis C.
Rajani AK, Ravindra BK, Dkhar SA.
J Postgrad Med. 2013 Jan-Mar;59(1):42-7. doi: 10.4103/0022-3859.109493.
